[68Ga]Ga-DOTA-TATE

DRUG4 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Extensive Stage Small Cell Lung CancerGlioblastomaMetastatic Neuroendocrine Prostate CancerNeuroendocrine Neoplasms

Phase 1

A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

Active, not recruitingNCT05109728

Novartis PharmaceuticalsGlioblastoma

Start: 2022-05-10End: 2027-07-31Updated: 2026-03-16

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

Active, not recruitingNCT05142696

Novartis PharmaceuticalsExtensive Stage Small Cell Lung Cancer

Start: 2022-07-13End: 2029-03-23Updated: 2026-03-17

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Active, not recruitingNCT06379217

Novartis PharmaceuticalsMetastatic Neuroendocrine Prostate Cancer

Start: 2024-07-29End: 2026-08-27Updated: 2026-03-11

Phase 3

A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan

CompletedNCT06240741

Novartis PharmaceuticalsNeuroendocrine Neoplasms

Start: 2024-03-21End: 2024-12-27Updated: 2026-02-03

Related Papers

RTID-05. TRIAL IN PROGRESS: DOSE-FINDING STUDY AND EVALUATION OF [177LU]LU-DOTA-TATE IN COMBINATION WITH STANDARD OF CARE IN NEWLY DIAGNOSED GLIOBLASTOMA AND AS A SINGLE AGENT IN RECURRENT GLIOBLASTOMA

Neuro-Oncology2022-11-011 citations